SCHEMBL2118065

SCHEMBL2118065

Cc1ccc(S(=O)(=O)Nc2cc(-c3ccc(C#N)cn3)ccc2C)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
TP53 P04637 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HPGD P15428 3/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
S1PR4 O95977 1/20 0.40
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
S1PR1 P21453 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KIT P10721 1/20 0.40
SGK1 O00141 2/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPT P10636 2/20 0.39
HSD11B1 P28845 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119273 0.84 KDM4E (0.53) ALDH1A1TP53MEN1KMT2AHPGD
SCHEMBL2117509 0.83 ACLY (0.42) ALDH1A1MEN1KMT2ASGK1KDM4E
SCHEMBL2117860 0.82 HSD11B1 (0.40) TP53MEN1KMT2ASMN1; SMN2SGK1
SCHEMBL2119497 0.82 MAPT (0.44) ALDH1A1TP53MEN1KMT2AHPGD
SCHEMBL2119726 0.80 KDM1A (0.48) TP53SMN1; SMN2MAPTHSD11B1THRB
SCHEMBL2122713 0.80 HSD11B1 (0.47) TP53SMN1; SMN2MAPTHSD11B1THRB
SCHEMBL2119034 0.80 TP53 (0.52) ALDH1A1TP53SMN1; SMN2MAPTHSD11B1
SCHEMBL2119426 0.79 SGK1 (0.45) ALDH1A1TP53SGK1HSD11B1ACLY
SCHEMBL2120060 0.78 HSD11B1 (0.45) TP53SGK1MAPTHSD11B1KDM1A
SCHEMBL2117136 0.78 TP53 (0.42) TP53SMN1; SMN2SGK1MAPTHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 ALDH1A1 1063/4885TP53 249/4885MEN1 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.